DB10804ApprovedInvestigationalWithdrawnOrganism Based TherapiesLive Attenuated Bacillus Calmette-Guerin Immunotherapy
Bacillus calmette-guerin substrain connaught live antigen is intravesically administered for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or... The solution contains live, attenuated strain of Mycobacterium bovis.
- Primary indication
- Indicated for intravesical use in the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection...Curator reviewed · 7 structured indications
- First approval
- Canada, 2005 · United States, 2011
- Also known as
- BCG, Live, Connaught Strain
Resolves to
Compound
Clinical / RWD
What you can answer from here — as of October 04, 2026
Which other approved drugs treat the same conditions as Bacillus calmette-guerin substrain connaught live antigen, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account